Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Cardioprotective Effects of Dapagliflozin and Exenatide

FY 2016-17

Summary
Ischemic cardiovascular disease (CVD) affects a high proportion of the world population. Subjects with type-2 diabetes (T2D) are at particularly high risk of major adverse cardiovascular events (MACE), with CVD representing their leading cause of morbidity and mortality. Following myocardial infarction (MI), timely reperfusion of occluded coronary flow is needed to rescue ischemic myocardium, as MI size is the most powerful predictor of prognosis. Paradoxically, reperfusion of ischemic myocardium results in an additional ‘ischemia-reperfusion injury’ (IRI), which accounts for ~50% of final MI size. Although a few pharmacological agents have been tested in Phase II/III studies of IRI, there remains no approved clinical therapy for this condition. Recently, two classes of anti-diabetic drugs, namely the sodium glucose cotransporter-2 inhibitors (SGLT2i) and the glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of MACE, including death and MI, in high risk subjects with T2D. However, the mechanisms underlying these benefits are not understood. It is also not known which of these two seemingly beneficial approaches may be best suited to preventing IRI post-MI. We propose to compare the IRI-preventive effects of the SGLT2i dapagliflozin (Dapa) vs. the GLP-1RA exenatide (Ex-4) vs. combination therapy in pre-clinical models of IRI. To achieve this, diabetic and non-diabetic mice will be randomized to 7-d pre-treatment with Dapa, Ex-4, or combination prior to in vivo IRI. Day 2 post-IRI, mice will be evaluated based on common mediators of IRI: infarct size and cardiac function, altered myocardial metabolism, oxidative stress-induced microvascular dysfunction, apoptosis, and thrombosis.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367395
Name
Zarrin Khat Dorrin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cardioprotective Effects of Dapagliflozin and Exenatide
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiac Remodeling And Dysfunction; Cardioprotective Agents; Heart Failure; Ischemia Reperfusion Injury; Myocardial Infarction; Myocardial Metabolism; Oxidative Stress And Apoptosis; Pharmacological Intervention; Thrombosis; Type Ii Diabetes
Abstract
Ischemic cardiovascular disease (CVD) affects a high proportion of the world population. Subjects with type-2 diabetes (T2D) are at particularly high risk of major adverse cardiovascular events (MACE), with CVD representing their leading cause of morbidity and mortality. Following myocardial infarction (MI), timely reperfusion of occluded coronary flow is needed to rescue ischemic myocardium, as MI size is the most powerful predictor of prognosis. Paradoxically, reperfusion of ischemic myocardium results in an additional ‘ischemia-reperfusion injury’ (IRI), which accounts for ~50% of final MI size. Although a few pharmacological agents have been tested in Phase II/III studies of IRI, there remains no approved clinical therapy for this condition. Recently, two classes of anti-diabetic drugs, namely the sodium glucose cotransporter-2 inhibitors (SGLT2i) and the glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of MACE, including death and MI, in high risk subjects with T2D. However, the mechanisms underlying these benefits are not understood. It is also not known which of these two seemingly beneficial approaches may be best suited to preventing IRI post-MI. We propose to compare the IRI-preventive effects of the SGLT2i dapagliflozin (Dapa) vs. the GLP-1RA exenatide (Ex-4) vs. combination therapy in pre-clinical models of IRI. To achieve this, diabetic and non-diabetic mice will be randomized to 7-d pre-treatment with Dapa, Ex-4, or combination prior to in vivo IRI. Day 2 post-IRI, mice will be evaluated based on common mediators of IRI: infarct size and cardiac function, altered myocardial metabolism, oxidative stress-induced microvascular dysfunction, apoptosis, and thrombosis.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zarrin Khat, Dorrin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~